Laboratory implementation of human papillomavirus testing.
Human papillomavirus testing is becoming an integral component of cervical cancer screening. Market forces will require most laboratories that perform Papanicolaou tests to develop a system for handling human papillomavirus testing also. Data and information are presented that may facilitate laboratories when addressing the following issues in the process of developing a human papillomavirus testing service: Which methodology is the best fit for the laboratory? Is it better to develop an in-house testing service or to send it out? How do I get started? What are the financial and economic issues, and how should they be managed?
Bolick
David R
DR
AmeriPath-Utah, Sandy, Utah 84070, USA. bolick@rpslab.com
Bolick
Randall E
RE
Coates
Faye
F
Daniels
Craig M
CM
Juretich
Michael B
MB
Lin
Kirk Ke
KK
Piper
Barbara L
BL
Cummings
Lisa
L
Rosenfeld
Mark J
MJ
Spangler
Frank L
FL
Staley
Brian E
BE
Willmore
Bradford E
BE
Willmore
Douglas
D
D005260:Female; D006801:Humans; D007753:Laboratories / Q000191:economics / Q000592:standards*; D025202:Molecular Diagnostic Techniques / Q000191:economics / Q000592:standards; D065006:Papanicolaou Test; D027383:Papillomaviridae / Q000302:isolation & purification*; D030361:Papillomavirus Infections / Q000473:pathology*; D014412:Tumor Virus Infections / Q000473:pathology*; D002583:Uterine Cervical Neoplasms / Q000473:pathology / Q000821:virology*; D014626:Vaginal Smears / Q000191:economics / Q000379:methods / Q000592:standards